Press

Another success for BDD's patented OralogiK™ technology with positive clinical results for colon

Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin Targeted colonic delivery shown Drug well-tolerated WAKEFIELD, MA – February 13, 2020 (GLOBE NEWSW IRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce that preliminary top-line data from its Phase 1 trial (NCT03234465) studying the use of delayed-release tablets of Brilacidin showed the trial met its primary endpoints. In the study, the timed-release OralogiK™ formulation of Brilacidin was radiolabeled (with complexed technetium-99m) and evaluated for safety and colonic deli

Featured Posts
Recent Posts
Archive
Follow Us
  • LinkedIn Social Icon
  • Twitter Basic Square

          BDD Ltd

 

CLINICAL SITE:   BDD Pharma Ltd

Glasgow Royal Infirmary

84 Castle St

Glasgow

G4 0SF, UK

FORMULATION SITE:  BDD Pharma Ltd

Bio-City Scotland

Bo'ness Road

Chapelhall, Newhouse

ML1 5UH, UK

Contact Us

Clinical Site. +44 (0)141 552 8791

Formulation site. +44 (0)141 552 7752

email. enquiries@bddpharma.com

 

Social Media

  • LinkedIn - White Circle
  • Twitter - White Circle
  • YouTube - White Circle
  • Facebook - White Circle

Registered in Scotland No. 212868        Privacy Policy     Acceptable Use     Terms of Use   

@2020 BDD Ltd